pyridoxal phosphate has been researched along with Stroke in 8 studies
Pyridoxal Phosphate: This is the active form of VITAMIN B 6 serving as a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. During transamination of amino acids, pyridoxal phosphate is transiently converted into pyridoxamine phosphate (PYRIDOXAMINE).
pyridoxal 5'-phosphate : The monophosphate ester obtained by condensation of phosphoric acid with the primary hydroxy group of pyridoxal.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Epidemiological studies have described an association between low vitamin B6 (measured as pyridoxal 5'-phosphate [PLP]) and ischemic stroke, independent of homocysteine (tHcy)." | 7.72 | Inflammation, homocysteine, and vitamin B6 status after ischemic stroke. ( Atassi, N; Barron, M; Furie, KL; Kelly, PJ; Kistler, JP; Lee, H; Mandell, R; Shih, VE; Silveira, S, 2004) |
| "We investigated the relation between the ratio plasma 4-pyridoxic acid: (pyridoxal + pyridoxal-5'-phosphate) (PAr) as an indicator of altered vitamin B-6 homeostasis and the risk of stroke in the general population." | 3.88 | The PAr index, an indicator reflecting altered vitamin B-6 homeostasis, is associated with long-term risk of stroke in the general population: the Hordaland Health Study (HUSK). ( Meyer, K; Midttun, Ø; Nygård, O; Tell, GS; Ueland, PM; Ulvik, A; Vollset, SE; Zuo, H, 2018) |
| "Epidemiological studies have described an association between low vitamin B6 (measured as pyridoxal 5'-phosphate [PLP]) and ischemic stroke, independent of homocysteine (tHcy)." | 3.72 | Inflammation, homocysteine, and vitamin B6 status after ischemic stroke. ( Atassi, N; Barron, M; Furie, KL; Kelly, PJ; Kistler, JP; Lee, H; Mandell, R; Shih, VE; Silveira, S, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zuo, H | 1 |
| Tell, GS | 1 |
| Ueland, PM | 1 |
| Nygård, O | 1 |
| Vollset, SE | 1 |
| Midttun, Ø | 1 |
| Meyer, K | 1 |
| Ulvik, A | 1 |
| Lämmer, AB | 1 |
| Beck, A | 1 |
| Grummich, B | 1 |
| Förschler, A | 1 |
| Krügel, T | 1 |
| Kahn, T | 1 |
| Schneider, D | 1 |
| Illes, P | 1 |
| Franke, H | 1 |
| Krügel, U | 1 |
| Kelly, PJ | 2 |
| Shih, VE | 2 |
| Kistler, JP | 2 |
| Barron, M | 2 |
| Lee, H | 2 |
| Mandell, R | 2 |
| Furie, KL | 2 |
| Atassi, N | 1 |
| Silveira, S | 1 |
| Tsuda, K | 1 |
| Nishio, I | 1 |
| Verrier, ED | 1 |
| Tardif, JC | 1 |
| Carrier, M | 1 |
| Kandzari, DE | 1 |
| Emery, R | 1 |
| Cote, R | 1 |
| Heinonen, T | 1 |
| Zettler, M | 1 |
| Hasselblad, V | 1 |
| Guertin, MC | 1 |
| Harrington, RA | 1 |
| Miller, JW | 1 |
| Green, R | 1 |
| Mungas, DM | 1 |
| Reed, BR | 1 |
| Jagust, WJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Hordaland Health Studies (HHS)[NCT03013725] | 36,000 participants (Actual) | Observational | 1992-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for pyridoxal phosphate and Stroke
| Article | Year |
|---|---|
Effects of pyridoxal-5'-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: results of the MEND-CABG randomized study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Area Under Curve; Canada; Cardiopulmonary Bypa | 2007 |
7 other studies available for pyridoxal phosphate and Stroke
| Article | Year |
|---|---|
The PAr index, an indicator reflecting altered vitamin B-6 homeostasis, is associated with long-term risk of stroke in the general population: the Hordaland Health Study (HUSK).
Topics: Aged; Body Mass Index; C-Reactive Protein; Exercise; Female; Follow-Up Studies; Health Surveys; Home | 2018 |
The P2 receptor antagonist PPADS supports recovery from experimental stroke in vivo.
Topics: Animals; Cell Death; Electroencephalography; Immunohistochemistry; In Situ Nick-End Labeling; Infarc | 2011 |
Low vitamin B6 but not homocyst(e)ine is associated with increased risk of stroke and transient ischemic attack in the era of folic acid grain fortification.
Topics: Case-Control Studies; Comorbidity; Edible Grain; Female; Folic Acid; Food, Fortified; Homocysteine; | 2003 |
Inflammation, homocysteine, and vitamin B6 status after ischemic stroke.
Topics: Aged; Brain Ischemia; C-Reactive Protein; Comorbidity; Female; Homocysteine; Humans; Inflammation; M | 2004 |
Homocysteine, vitamin B6, and endothelial dysfunction in circulatory disorders.
Topics: Arginine; C-Reactive Protein; Endothelium, Vascular; Homocysteine; Humans; Nitric Oxide; Pyridoxal P | 2004 |
Translational research: is there a future?
Topics: Administration, Oral; Cardiopulmonary Bypass; Cardiovascular Diseases; Coronary Artery Bypass; Creat | 2007 |
Homocysteine, vitamin B6, and vascular disease in AD patients.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Angina Pectoris; Brain Infarction; Coronary Disease; Fem | 2002 |